Hepatitis C genotype 3 disease. (Q30244065)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

review article

1 reference

title

Hepatitis C genotype 3 disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Shyam Kottilil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sarah Kattakuzhy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Rachel Levy

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Lydia Tang

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

21 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

published in

Hepatology international

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

861-870

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27328848%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology and genotype distribution of the hepatitis C virus infection

14 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9748-Z

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27328848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27328848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27328848